BR0316865A - Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncer - Google Patents
Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncerInfo
- Publication number
- BR0316865A BR0316865A BR0316865-4A BR0316865A BR0316865A BR 0316865 A BR0316865 A BR 0316865A BR 0316865 A BR0316865 A BR 0316865A BR 0316865 A BR0316865 A BR 0316865A
- Authority
- BR
- Brazil
- Prior art keywords
- camptothecin derivative
- topoisomerase inhibitor
- converting
- nucleic acid
- variant
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 5
- 102000021944 Butyrylcholinesterase Human genes 0.000 title abstract 4
- 108010053652 Butyrylcholinesterase Proteins 0.000 title abstract 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 3
- 101710183280 Topoisomerase Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31066602A | 2002-12-04 | 2002-12-04 | |
| PCT/US2003/038684 WO2004050041A2 (en) | 2002-12-04 | 2003-12-04 | Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316865A true BR0316865A (pt) | 2005-10-25 |
Family
ID=32468084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316865-4A BR0316865A (pt) | 2002-12-04 | 2003-12-04 | Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080213281A1 (https=) |
| EP (1) | EP1581253A4 (https=) |
| JP (1) | JP2006508665A (https=) |
| CN (1) | CN100341568C (https=) |
| AU (1) | AU2003298920A1 (https=) |
| BR (1) | BR0316865A (https=) |
| CA (1) | CA2507626A1 (https=) |
| MX (1) | MXPA05005996A (https=) |
| WO (1) | WO2004050041A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US20090208480A1 (en) * | 2006-08-04 | 2009-08-20 | Yue Huang | Long half-life recombinant butyrylcholinesterase |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| CA2723821C (en) * | 2008-05-16 | 2017-05-02 | Nektar Therapeutics | Conjugates of a cholinesterase moiety and a polymer |
| JP2013526840A (ja) | 2009-12-21 | 2013-06-27 | ファーマシーネ，インコーポレイテッド | 組み換えブチリルコリンエステラーゼおよびその切断型 |
| CN103898101B (zh) * | 2012-12-27 | 2017-08-08 | 上海桀蒙生物技术有限公司 | 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法 |
| CN104630177A (zh) * | 2013-11-08 | 2015-05-20 | 中国农业大学 | 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法 |
| US10301609B2 (en) | 2014-04-29 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin |
| WO2018053216A1 (en) * | 2016-09-15 | 2018-03-22 | Mayo Foundation For Medical Education And Research | Methods and materials for using butyrylcholinesterases to treat cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0378576B1 (en) * | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264563A (en) * | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| US5506125A (en) * | 1993-12-22 | 1996-04-09 | Agracetus, Inc. | Gene delivery instrument with replaceable cartridges |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6001625A (en) * | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| CA2330829C (en) * | 1998-06-16 | 2011-08-02 | Variagenics, Inc. | Methods for treating a neurological disease by determining bche genotype |
| CN1331339A (zh) * | 2000-06-26 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸 |
| US7070973B2 (en) * | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| WO2002064796A2 (en) * | 2000-12-26 | 2002-08-22 | Applied Molecular Evolution, Inc. | Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| US20030153062A1 (en) * | 2001-12-20 | 2003-08-14 | Watkins Jeffry D. | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
-
2003
- 2003-12-04 WO PCT/US2003/038684 patent/WO2004050041A2/en not_active Ceased
- 2003-12-04 AU AU2003298920A patent/AU2003298920A1/en not_active Abandoned
- 2003-12-04 CA CA002507626A patent/CA2507626A1/en not_active Abandoned
- 2003-12-04 EP EP03796682A patent/EP1581253A4/en not_active Withdrawn
- 2003-12-04 BR BR0316865-4A patent/BR0316865A/pt not_active IP Right Cessation
- 2003-12-04 CN CNB2003801050807A patent/CN100341568C/zh not_active Expired - Fee Related
- 2003-12-04 MX MXPA05005996A patent/MXPA05005996A/es not_active Application Discontinuation
- 2003-12-04 JP JP2004557611A patent/JP2006508665A/ja active Pending
- 2003-12-04 US US10/535,441 patent/US20080213281A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2507626A1 (en) | 2004-06-17 |
| AU2003298920A1 (en) | 2004-06-23 |
| JP2006508665A (ja) | 2006-03-16 |
| EP1581253A4 (en) | 2007-02-14 |
| MXPA05005996A (es) | 2006-04-18 |
| WO2004050041A3 (en) | 2004-10-28 |
| EP1581253A2 (en) | 2005-10-05 |
| WO2004050041A2 (en) | 2004-06-17 |
| CN1720063A (zh) | 2006-01-11 |
| CN100341568C (zh) | 2007-10-10 |
| US20080213281A1 (en) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004035747A3 (en) | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| ATE308979T1 (de) | Lipasehemmende polymere | |
| BRPI0407207A (pt) | Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter | |
| TNSN06010A1 (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
| BR0310092A (pt) | Combinação de compostos orgânicos | |
| EP1581656A4 (en) | MODULATION OF THE EXPRESSION OF HIF1a AND HIF2a | |
| BR0316865A (pt) | Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncer | |
| DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
| EP1505990A4 (en) | METHOD FOR THE TREATMENT OF HEPATITIS | |
| CY1111703T1 (el) | Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους | |
| NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
| PL374865A1 (en) | Treatment of tnf alpha related disorders | |
| BR0215622A (pt) | Inibidores da dpiv com base em glutaminila | |
| BRPI0414794A (pt) | oxadiazolidinadionas substituìdas | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| MX2009001342A (es) | Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion. | |
| WO2008043052A3 (en) | Human antibodies neutralizing human metapneumovirus | |
| BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
| ATE293691T1 (de) | Myostatin genpromoter und inhibierung dessen aktivierung | |
| ATE430572T1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
| NO20072290L (no) | Organiske forbindelser. | |
| WO2004031105A3 (en) | Use of a33 antigens and jam-it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |